UPC rejects Alexion’s rehearing bid in spat with Amgen and Samsung

Court sets strict rules on rehearing's, saying "only fundamental procedural defects can be the basis for a rehearing” | Follows UK blow to Alexion, allowing biosimilars onto market.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

IP in the deal room: The risks that bite before, during and after closing

7 May 2026 Experts from Johnson & Johnson and Novartis took the stage at INTA to share the pitfalls lurking inside mergers, acquisitions and spin-offs and what in-house counsel can do about them.

Europe

Five generations at work: How teams are bridging the gap

6 May 2026 Panellists at INTA share how workplaces can bridge generational divides and why those differences may be a team’s biggest strengths.

Europe

WATCH: John Ward, trademarks VP and associate GC of Moderna, at INTA

5 May 2026 John Ward, vice president and associate general counsel of trademarks at Moderna, chats with Tom Phillips at INTA 2026.